

Special Issue

Utilization of Non-human Viruses as Recombinant Vector Vaccines against Newly Emerging Human Viral Diseases

Message from the Guest Editors

I am delighted to invite you to contribute your research to this Special Issue, titled “*Utilization of Non-Human Viruses as Recombinant Vector Vaccines Against Newly Emerging Human Viral Diseases*”. This Special Issue aims to showcase recent research and advancements in using non-human viruses as vectors, highlighting their benefits, challenges, and future directions. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: non-human viruses, recombinant vector vaccines, emerging human viral diseases, vaccine development, immunogenicity, the immune response, comparative vaccine studies, and clinical trials. I look forward to receiving your contributions. Keywords

- recombinant vector vaccines
- non-human viruses (herpesviruses, adenoviruses, poxviruses, and baculoviruses)
- vaccine development
- immunogenicity
- immune response
- comparative vaccine studies
- clinical trials

Guest Editors

Dr. Dayan Wang

Chinese Center for Disease Control and Prevention, Beijing, China

Dr. Abdo Said

The Hospital for Sick Children (SickKids) Peter Gilgan Centre for Research and Learning 686 Bay Street, Toronto, ON M5G 0A4, Canada

Deadline for manuscript submissions

31 January 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/202049

Vaccines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).